You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信達生物(01801.HK)續升7%曾見38.75元新高 肺癌新藥銷情理想獲瑞信升價
阿思達克 04-24 14:44
信達生物製藥(01801.HK)治療肺癌新適應症之新藥信迪利單抗注射液上市申請獲受理及該藥首季銷情較瑞信預測高30%,該股承昨天重越10天線勢,今天曾進一步突破2月所創上市高位37.9元,最高見38.75元,現造37.3元,續升7%,成交已達525萬股,涉資1.95億元。

信達公布,集團與禮來製藥共同開發治療肺癌新適應症之新藥「信迪利單抗注射液」上市申請已正式獲國家藥品監督管理局受理。該藥物首季銷售收入約4億人民幣,瑞信指金額較該行預測高約30%,加上該藥已納入國家醫保後會有更佳醫院取用及降價後更能負擔等原因,料該藥在今年餘下時間銷售會增加,故將該藥全年銷售預測由原先15.1億元升至19.6億元人民幣。同時。調高信達生物今明兩年收入預測33%及15%,以及其目標價由38元,升至41.5元,重申「跑贏大市」評級。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account